Drug Profile

Research programme: PSMA targeted T cell engagers - Xilio Therapeutics

Latest Information Update: 20 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xilio Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Feb 2025 Xilio Therapeutics plans to submit IND application for PSMA program in the first quarter of 2027
12 Feb 2025 Early research in Prostate cancer in USA (Parenteral)
12 Feb 2025 Xilio Therapeutics anticipates nominating a development candidate for PSMA program in the ATACR format in the third quarter of 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com